{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:51:52Z","timestamp":1785531112845,"version":"3.56.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1136\/ard-2023-224472","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T17:20:40Z","timestamp":1695144040000},"page":"103-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Short-term effectiveness and safety of rituximab versus cyclophosphamide for life-threatening ANCA-associated vasculitis: a propensity score analysis of the real-world nationwide database"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7406-2309","authenticated-orcid":false,"given":"Yuichi","family":"Ishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Tokutsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Nakayamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Kuchiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1894-0290","authenticated-orcid":false,"given":"Kiyohide","family":"Fushimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2023-224472_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","article-title":"ANCA-associated vasculitis","volume":"6","author":"Kitching","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1136\/ard-2023-224472_bib2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1053\/j.ajkd.2009.10.047","article-title":"Prediction of ESRD in Pauci-immune necrotizing glomerulonephritis: quantitative histomorphometric assessment and serum creatinine","volume":"55","author":"Day","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1136\/ard-2023-224472_bib3","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1681\/ASN.2014010046","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement","volume":"26","author":"Geetha","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1136\/ard-2023-224472_bib4","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3109\/14397595.2016.1140274","article-title":"Comparison of severity classification in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study","volume":"26","author":"Sada","year":"2016","journal-title":"Mod Rheumatol"},{"key":"10.1136\/ard-2023-224472_bib5","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3109\/s10165-011-0525-5","article-title":"Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study","volume":"22","author":"Ozaki","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1136\/ard-2023-224472_bib6","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"American college of rheumatology\/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224472_bib7","first-page":"476","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"82","author":"Hellmich","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224472_bib8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-224472_bib9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-224472_bib10","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2023-224472_bib11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1253\/circj.CJ-19-0773","article-title":"JCS 2017 guideline on management of vasculitis syndrome - digest version","volume":"84","author":"Isobe","year":"2020","journal-title":"Circ J"},{"issue":"Suppl 1","key":"10.1136\/ard-2023-224472_bib12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/1756-185X.13398","article-title":"Is granulomatosis with polyangiitis in Asia different from the West","volume":"22","author":"Naidu","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1136\/ard-2023-224472_bib13","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/mr\/roab088","article-title":"Nation-wide survey of the treatment trend of microscopic polyangiitis and granulomatosis with polyangiitis in Japan using the Japanese ministry of health","volume":"32","author":"Nagasaka","year":"2022","journal-title":"Mod Rheumatol"},{"key":"10.1136\/ard-2023-224472_bib14","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.42515","article-title":"Comparative effectiveness of rituximab\u2010 versus cyclophosphamide\u2010based remission induction strategies in antineutrophil cytoplasmic antibody\u2013associated vasculitis for the risk of kidney failure and mortality","volume":"75","author":"Wallace","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224472_bib15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2188\/jea.JE20170022","article-title":"Efficacy of antimicrobial catheters for prevention of catheter-associated urinary tract infection in acute cerebral infarction","volume":"28","author":"Muramatsu","year":"2018","journal-title":"J Epidemiol"},{"key":"10.1136\/ard-2023-224472_bib16","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4269\/ajtmh.2010.09-0780","article-title":"Clinical features of bowel anisakiasis in Japan","volume":"83","author":"Yasunaga","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"10.1136\/ard-2023-224472_bib17","first-page":"35","article-title":"Development of case mix based evaluation system in Japan","author":"Matsuda","year":"2016","journal-title":"Jpn Hosp"},{"key":"10.1136\/ard-2023-224472_bib18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jjcc.2016.05.008","article-title":"Factors affecting in-hospital mortality and likelihood of undergoing surgical resection in patients with primary cardiac tumors","volume":"69","author":"Isogai","year":"2017","journal-title":"J Cardiol"},{"key":"10.1136\/ard-2023-224472_bib19","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/CCM.0000000000000150","article-title":"Postoperative polymyxin B hemoperfusion and mortality in patients with abdominal septic shock: a propensity-matched analysis","volume":"42","author":"Iwagami","year":"2014","journal-title":"Crit Care Med"},{"key":"10.1136\/ard-2023-224472_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001508","article-title":"Estimation of treatment and prognostic factors of pneumocystis pneumonia in patients with connective tissue diseases","volume":"7","author":"Ishikawa","year":"2021","journal-title":"RMD Open"},{"key":"10.1136\/ard-2023-224472_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.843809","article-title":"Short-term Prognostic factors in hospitalized herpes zoster patients and its associated cerebro-cardiovascular events: a nationwide retrospective cohort in Japan","volume":"9","author":"Ishikawa","year":"2022","journal-title":"Front Med"},{"key":"10.1136\/ard-2023-224472_bib22","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1681\/ASN.2019111197","article-title":"Efficacy of rituximab and plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis with severe kidney disease","volume":"31","author":"Casal Moura","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1136\/ard-2023-224472_bib23","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/rheumatology\/ker205","article-title":"Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K","volume":"50","author":"Fujimoto","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224472_bib24","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1007\/s10157-021-02096-7","article-title":"A Digest of the evidence-based clinical practice guideline for rapidly progressive glomerulonephritis 2020","volume":"25","author":"Usui","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"10.1136\/ard-2023-224472_bib25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/ndt\/5.1.10","article-title":"Association of glomerular and interstitial mononuclear leukocytes with different forms of glomerulonephritis","volume":"5","author":"Markovic-Lipkovski","year":"1990","journal-title":"Nephrol Dial Transplant"},{"key":"10.1136\/ard-2023-224472_bib26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.15171\/jnp.2017.16","article-title":"Differences in the frequency of macrophage and T cell markers between focal and crescentic classes of anti-neutrophil cytoplasmic antibody (ANCA)-Associated glomerulonephritis","volume":"6","author":"Kidder","year":"2017","journal-title":"J Nephropathol"},{"key":"10.1136\/ard-2023-224472_bib27","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1172\/JCI97879","article-title":"Bowman's capsule provides a protective niche for podocytes from cytotoxic Cd8+ T cells","volume":"128","author":"Chen","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1136\/ard-2023-224472_bib28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","article-title":"Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies","volume":"170","author":"Xiao","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1136\/ard-2023-224472_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102424","article-title":"Complement alternative pathway in ANCA-associated vasculitis: two decades from bench to bedside","volume":"19","author":"Brilland","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard-2023-224472_bib30","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13075-020-02215-x","article-title":"Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation","volume":"22","author":"Miyazaki","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-224472_bib31","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.43799","article-title":"Rituximab vs cyclophosphamide induction therapy for patients with granulomatosis with polyangiitis","volume":"5","author":"Pu\u00e9chal","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1136\/ard-2023-224472_bib32","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1086\/526778","article-title":"Early predictors of mortality from pneumocystis Jirovecii pneumonia in HIV-infected patients: 1985-2006","volume":"46","author":"Walzer","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1136\/ard-2023-224472_bib33","article-title":"Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people","volume":"8","author":"Awotiwon","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/ard-2023-224472_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02668","article-title":"Mechanisms of graft-versus-host disease prevention by post-transplantation cyclophosphamide: an evolving understanding","volume":"10","author":"Nunes","year":"2019","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2023-224472_bib35","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1182\/blood.2020010028","article-title":"Immune control of cytomegalovirus reactivation in stem cell transplantation","volume":"139","author":"Degli-Esposti","year":"2022","journal-title":"Blood"},{"key":"10.1136\/ard-2023-224472_bib36","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1126\/science.aat0066","article-title":"Strain-specific antibody therapy prevents cytomegalovirus reactivation after transplantation","volume":"363","author":"Martins","year":"2019","journal-title":"Science"},{"key":"10.1136\/ard-2023-224472_bib37","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-Cd20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1136\/ard-2023-224472_bib38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.7223\/apjdm.7.19","article-title":"Clinical epidemiology and health services research using the diagnosis procedure combination database in Japan","volume":"7","author":"Yasunaga","year":"2015","journal-title":"Asian Pacific Journal of Disease Management"},{"key":"10.1136\/ard-2023-224472_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2188\/jea.JE20200288","article-title":"History and profile of diagnosis procedure combination (DPC): development of a real data collection system for acute inpatient care in Japan","volume":"31","author":"Hayashida","year":"2021","journal-title":"J Epidemiol"},{"key":"10.1136\/ard-2023-224472_bib40","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.je.2016.09.009","article-title":"Validity of diagnoses, procedures, and laboratory data in Japanese administrative data","volume":"27","author":"Yamana","year":"2017","journal-title":"J Epidemiol"},{"key":"10.1136\/ard-2023-224472_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2021.102016","article-title":"Validity of initial cancer diagnoses in the diagnosis procedure combination data in Japan","volume":"74","author":"Shigemi","year":"2021","journal-title":"Cancer Epidemiol"},{"key":"10.1136\/ard-2023-224472_bib42","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/pds.4116","article-title":"Development and validation of case-finding algorithms for the identification of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis in large healthcare administrative databases","volume":"25","author":"Sreih","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1136\/ard-2023-224472_bib43","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1002\/art.40577","article-title":"Epidemiology and outcomes of granulomatosis with polyangiitis in pediatric and working-age adult populations in the United States: analysis of a large national claims database","volume":"70","author":"Panupattanapong","year":"2018","journal-title":"Arthritis Rheumatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724003947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724003947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2023-224472","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T04:45:53Z","timestamp":1737348353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724003947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0003496724003947"],"URL":"https:\/\/doi.org\/10.1136\/ard-2023-224472","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short-term effectiveness and safety of rituximab versus cyclophosphamide for life-threatening ANCA-associated vasculitis: a propensity score analysis of the real-world nationwide database","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-224472","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}